Article
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Oct 2017
Cho J, Kim S Y, Kim Y J, Sim M H, Kim S T, Kim N K D, Kim K, Park W, Kim J H, Jang K-T, Lee J
Abstract excerpt
PURPOSE: The KIT inhibitor, imatinib, has shown promising efficacy in patients with KIT-mutated melanoma; however, acquisition of resistance to imatinib occurs rapidly in the majority of patients. The mechanisms of acquired resistance to imatinib in melanoma remain unclear. METHODS: We analyzed biopsy samples from paired baseline and post-treatment tumor lesions in one patient with KIT-mutated melanoma who had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.